Clinical trials: Venous Thromboembolic Event
Cardiovascular Diseases, Venous Thromboembolism
LEAVE Safe With DOACs
Given the risks associated with direct oral anticoagulants (DOACs) and the lack of defined pathways for patients prescribed this class of medications, the study intervention has the potential for an enormous impact in preventing…
- Conditions
- Cardiovascular Diseases, Venous Thromboembolism, Atrial Fibrillation, Bleeding
- Trial name
- NCT04068727
- Testing
- Clinical Pharmacist Intervention
- Where
- United States
- Volunteers
- 561 people
- Sponsor
- University of Massachusetts, Worcester
Arthroplasty, Replacement, Prevention of Venous Thromboembolism
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
To supplement the current evidence of the effect of Pradaxa® (dabigatran etexilate) on coagulation parameters, including a calibrated thrombin time test, in patients with moderate renal impairment undergoing elective total hip…
- Conditions
- Arthroplasty, Replacement, Prevention of Venous Thromboembolism, Moderate Renal Impairment (CrCl 30-50 mL/Min)
- Trial name
- NCT01184989
- Testing
- Dabigatran etexilate
- Where
- 10 sites in Austria, Canada and 4 more
- Volunteers
- 142 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs
To assess the safety and pharmacokinetics of DU-176b administered to patients with severe renal impairment undergoing orthopedic surgery of the lower limbs, compared with DU-176b administered to patients with mild renal…
- Trial name
- NCT01857583
- Testing
- 15mg DU-176b, 30mg DU-176b, Fondaparinux
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Venous Thromboembolism
A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement
This study is a multicenter, double-blind, randomized, prospective phase 2 dose ranging study to evaluate the safety and efficacy of Dimolegin - DD217 in prevention of venous thromboembolic complications in patients underwent…
- Trial name
- NCT05189002
- Testing
- Dimolegin 40 mg, Dimolegin 60 mg, Fragmin
- Where
- 15 sites in Russia
- Volunteers
- 240 people
- Sponsor
- PharmaDiall Ltd.
Deep Venous Thrombosis, Pulmonary Embolism
Risk Factors for Venous Thromboembolism
Deep venous thrombosis is the presence of blood clots, usually in the legs that lead to either local problems or breathing problems if the clot moves to the lungs.
- Trial name
- NCT00018772
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Venous Thrombosis
Using Intravenous Heparin Versus Standard of Care Subcutaneous Heparin to Prevent Clots After Surgery
This study plans to learn more about what is the best treatment to prevent blood clots in patients in intensive care units (ICU's).
- Trial name
- NCT01608906
- Testing
- low dose intravenous heparin (LDIVH), Heparin
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- University of Colorado, Denver
Venous Thromboembolism, Deep Vein Thrombosis
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
The objective of this study is to assess the efficacy, safety and dose-response relationship of DU-176b compared with placebo for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Total Knee Arthroplasty
- Trial name
- NCT01203072
- Testing
- DU-176b
- Where
- 2 sites in Japan
- Volunteers
- 523 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Post Thrombotic Syndrome, Chronic Thromboembolic Pulmonary Hypertension
Long Term Outcomes of Venous Thromboembolism
This prospective observational follow-up study is designed to assess the long-term outcomes after Venous thromboembolism (VTE) and to assess the effect of the new oral anticoagulant (NOAC) rivaroxaban on the prevalence of…
- Conditions
- Post Thrombotic Syndrome, Chronic Thromboembolic Pulmonary Hypertension, Venous Thrombosis
- Trial name
- LOVE (NCT02268630)
- Where
- 3 sites in Norway
- Volunteers
- 460 people
- Sponsor
- Ostfold Hospital Trust
Venous Thromboembolism (VTE)
A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US
A study involving real-world database analysis to evaluate the hospital healthcare utilization and costs, and all-cause, major bleeding-, clinically relevant bleeding-, any bleeding-, and venous thromboembolism (VTE)-related…
- Trial name
- NCT04141228
- Where
- United States
- Volunteers
- 28,000 people
- Sponsor
- Bristol-Myers Squibb
Thrombosis, Venous
A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery
The purpose of this study is to evaluate the efficacy and safety of fondaparinux in comparison with a heparin (nadroparin) in preventing deep vein thrombosis (blood clots in the leg veins), whether symptomatic or detected by…
- Trial name
- FONDACAST (NCT00843492)
- Testing
- Fondaparinux sodium, Nadroparin
- Where
- 122 sites in France, Germany and 4 more
- Volunteers
- 1,351 people
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism (VTE)
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery.
- Trial name
- ROXI-APEX (NCT07015905)
- Testing
- REGN7508, Apixaban, Enoxaparin
- Where
- 47 sites in United States, Bulgaria and 6 more
- Volunteers
- 2,000 people
- Sponsor
- Regeneron Pharmaceuticals
Cardiovascular Diseases
Molecular Investigation of Genetic Factors in CArDiovascular Diseases Using an BIOresource of Healthy Volunteers
The risk of cardiovascular disease is determined by the complex interplay between an individual's genetic make-up, lifestyle, and the environment.
- Trial name
- CADBIO (NCT03038750)
- Testing
- Eligibility and lifestyle restrictions check., Medical history, demographic and lifestyle factors, Anthropometric measurements: height, weight, and body fat
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Venous Thromboembolism
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
The purpose of this study is to compare the efficacy and safety of dalteparin vs unfractionated heparin for the prevention of VTE (Venous Thromboembolism) in hospitalized acutely ill medical patients.
- Trial name
- NCT00445328
- Testing
- Dalteparin (Fragmin), Unfractionated heparin
- Where
- 7 sites in India
- Volunteers
- 84 people
- Sponsor
- Pfizer
Deep Vein Thrombosis, Venous Thrombosis
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for…
- Trial name
- XALIA (NCT01619007)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care
- Where
- 21 sites in Austria, Belgium and 19 more
- Volunteers
- 5,145 people
- Sponsor
- Bayer
Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET)
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
Myeloproliferative neoplasms (MPNs) are blood disorders that occur when the body makes too many white or red blood cells, or platelets.
- Conditions
- Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET), JAK2 Mutation, Polycythemia Vera (PV)
- Trial name
- AIRPORT-MPN (NCT04243122)
- Testing
- Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thromboembolism
Thrombus Elastography in Venous Thrombo-Embolism.
Venous Thrombo-Embolic Disease (VTED) is a serious and common ailment, defined by the growth of a clot - or thrombus - in a vein, and/or as the migration of this thrombus to a pulmonary artery.
- Trial name
- TEVTE (NCT04130048)
- Testing
- Ultrasound Elastography
- Where
- France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Brest
Major Non-cardiac Surgeries
A Trial of a Hospital Policy of Tranexamic Acid Use to Reduce Transfusion in Major Non-cardiac Surgery
A Phase IV trial of a hospital policy of Tranexamic acid to reduce transfusion in major non-cardiac surgery.
- Trial name
- TRACTION (NCT04803747)
- Testing
- Tranexamic acid (TXA)
- Where
- 10 sites in Canada
- Volunteers
- 8,421 people
- Sponsor
- University of Manitoba
Venous Thromboembolism, Anticoagulant
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
The study aims at optimizing extended management of elderly patients (> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous thromboembolism of the lower extremity (proximal…
- Conditions
- Venous Thromboembolism, Anticoagulant, Elderly
- Trial name
- Jason (NCT04257487)
- Testing
- Sulodexide
- Where
- Italy
- Volunteers
- 1,455 people
- Sponsor
- Arianna Anticoagulazione Foundation
Cancer, Deep Venous Thrombosis
Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism
Cancer patients are at increased risk of deep venous thrombosis and pulmonary embolism, collectively termed venous thromboembolism (VTE).
- Conditions
- Cancer, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- MICA (NCT02095925)
- Where
- 7 sites in France, Italy and 2 more
- Volunteers
- 900 people
- Sponsor
- Harry R. Buller
Myotonic Dystrophy 1
Venous Thromboembolism in Myotonic Dystrophy Type 1
Investigators identified a high risk of deep vein thrombosis and pulmonary embolism in patients presenting myotonic dystrophy type 1 treated in our hospital, 10 times higher than general population matched on age and sex.
- Trial name
- DM1-VTE (NCT03424460)
- Testing
- Haemostasis tests, Monocytes and megacaryocytes culture and RNA extraction, RNA extraction
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris